Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Bayer’s Stivarga Gets Priority Review for Gastrointestinal Stromal Tumors

Drug Industry Daily

Oct. 30, 2012 | Vol. 11 No. 213

Bayer’s Stivarga Gets Priority Review for Gastrointestinal Stromal Tumors

Bayer HealthCare and Onyx Pharmaceuticals have won priority review for Stivarga to treat metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

FOIA Log Arbor Receives First FDA Drug Approval FDA Announces Plans to Audit Drug Application Transparency Initiative FDA Rejects Two Gilead HIV Drugs as Standalone Treatments

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.